Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Last trade$9.73
Day change-$0.40 (-3.95%)
Day range$9.61 – $10.23
Volume403,313
Market cap$729M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$728.71M
Price / earnings
—
Price / book
3.01×
Price / sales
—
EV / sales
—
EV / EBITDA
-10.32×
Profitability
Earnings per share
-$0.74
Return on assets
-18.9%
Return on equity
-22.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.34×
Quick ratio
6.34×
Cash ratio
2.92×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SGMT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.23M
$4.28M
$4.72M
$4.03M
$4.6M
$4.68M
$4.52M
$3.98M
Research and development
$16.34M
$11.54M
$7M
$6.73M
$9.73M
$7.25M
$15.34M
$14.22M
Total operating expenses
$21.57M
$15.82M
$11.71M
$10.77M
$14.33M
$11.93M
$19.87M
$18.2M
Operating income
-$21.57M
-$15.82M
-$11.71M
-$10.77M
-$14.33M
-$11.93M
-$19.87M
-$18.2M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$19.15M
-$13.95M
-$10.65M
-$9.57M
-$12.91M
-$10.39M
-$18.18M
-$16.2M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$19.15M
-$13.95M
-$10.65M
-$9.57M
-$12.91M
-$10.39M
-$18.18M
-$16.2M
Net income attributable to common shareholders
-$19.15M
-$13.95M
-$10.65M
-$9.57M
-$12.91M
-$10.39M
-$18.18M
-$16.2M
EBITDA
-$21.57M
-$15.82M
-$11.71M
-$10.77M
-$14.33M
-$11.93M
-$19.87M
-$18.2M
Basic earnings per share
-$0.31
-$0.26
-$0.33
-$0.29
-$0.40
-$0.32
-$0.56
-$0.50
Diluted earnings per share
-$0.31
-$0.26
-$0.33
-$0.29
-$0.40
-$0.32
-$0.56
-$0.50
Recent news
Company coverage with links to the original publishers.
Sagimet Biosciences (SGMT) has a mean analyst price target of $26.69, suggesting 168.2% upside potential from its current $9.95 price. The stock has a Zacks Rank #2 (Buy) rating with positive earnings estimate revisions, though the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions.
The acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.
Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat, a FASN inhibitor for moderate to severe acne, is on track to begin patient enrollment in Q4 2026. All clinical trial sites have been identified and a CRO has been retained, with patient screening expected to start in October 2026. The trial will enroll approximately 800 U.S. patients, including 450 adolescents, and if approved, denifanstat would be the first innovative oral acne treatment in over 40 years.
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced its inclusion in the Russell 3000 and Russell 2000 indexes effective June 29, 2026. The clinical-stage biopharmaceutical company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the second half of 2026. The company has sufficient capital to fund operations through 2028, including the denifanstat Phase 3 trial data readout.
Sagimet Biosciences announced management participation in the Leerink Partners Therapeutics Forum on July 15, 2026. The company also approved an inducement grant of 34,300 stock options to two newly hired employees as part of their employment compensation packages.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.